GlassScriptPhysician profile
Inderpreet Bhatia
NPI 1780358648
$2,493.10
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $602 · 2023: $935 · 2024: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869 · Education: $22.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.61 |
| Education | $22.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $532.72 | 2022-2024 | |
| Pfizer INC. | $347.28 | 2022-2024 | |
| Ucb, INC. | $263.82 | 2022-2024 | Briviact |
| Teva Pharmaceuticals USA, INC. | $249.19 | 2022-2024 | Ajovy, Austedo Xr, Austedo |
| Lilly USA, LLC | $186.29 | 2023-2024 | Kisunla, Amyvid, Reyvow |
| Lundbeck LLC | $109.27 | 2022-2024 | Vyepti |
| Biogen, INC. | $108.18 | 2023-2024 | Vumerity, Tysabri, Avonex |
| Tg Therapeutics, INC. | $80.46 | 2023-2024 | |
| Sk Life Science, INC. | $73.16 | 2022-2024 | |
| Scilex Pharmaceuticals INC. | $66.99 | 2023-2024 | Ztlido |
| Genzyme Corporation | $57.45 | 2022 | |
| Genentech USA, INC. | $46.81 | 2023 | Enspryng, Ocrevus |
| Neurelis, INC. | $46.39 | 2022 | |
| Horizon Therapeutics Plc | $43.45 | 2022-2023 | Uplizna |
| Eisai INC. | $40.76 | 2022-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $36.74 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.31 | 2023-2024 | Gammagard, Hyqvia |
| Acadia Pharmaceuticals INC | $22.05 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.55 | 2024 | Keveyis |
| Jazz Pharmaceuticals INC. | $19.10 | 2022 | |
| Averitas Pharma INC. | $18.16 | 2024 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $17.49 | 2023 | |
| Supernus Pharmaceuticals, INC. | $15.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.68 | 2022 | |
| Grifols USA, LLC | $14.43 | 2024 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $13.36 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.27 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inderpreet Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.